NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-24-076 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-233 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). To accomplish the stated over-arching goal, this NOFO will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities that either capitalize on existing networks of collaborating investigators or develop institute-based research education programs. Both research experiences and mentoring activities are required; research experiences are expected to be primary. Research Education Programs are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV/AIDS.
Funding Opportunity PAR-24-217 from the NIH Guide for Grants and Contracts. The purpose of this NIH HEAL Initiative PAIN Care Clinician Training Program: PCTP): Mentored Clinical Scientist Development Awards (K08) (Clinical Trials Required) is to support a cohort of new and well-trained, independent investigators. The program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas support by the NIH HEAL Initiatives Clinical Research in Pain Management program.
Notice NOT-AI-24-053 from the NIH Guide for Grants and Contracts
Notice NOT-NS-24-110 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-075 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-057 from the NIH Guide for Grants and Contracts. Stimulant Use Disorder still does not have FDA- approved treatments. Neuromodulation, such as, for example, transcranial magnetic stimulation (TMC) has been successfully used for more than 10 years in major depressive disorder (MDD) where patients have failed one antidepressant and since 2018 it has been used for obsessive-compulsive disorder (OCD). Another example is transcranial direct current stimulation (tDCS) which is currently being developed for a range of mental and neurological conditions, and some of them have direct relevance for StUD vulnerable phenotype (cognitive dysfunction, compulsive, and impulsive traits). Other neuromodulation technologies potentially can also be applied to StUD. As not everyone who takes drugs becomes addicted, and while the StUD population's extreme heterogeneity represents a barrier to effective treatment development, there is a treatment gap that needs to be filled, especially for the high-risk vulnerable phenotype with low executive function and difficulties with response regulation - anxious-impulsive traits. Developing neuromodulation combined with behavioral treatment modalities (CBT, mindfulness-based approaches) that will help to maintain use decrease and prevent relapse would have tremendous value as a treatment option. Randomized controlled trials are needed to develop the treatment algorithms and to select the most efficacious one.
Funding Opportunity PAR-24-244 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.
Funding Opportunity PAR-24-243 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.
Funding Opportunity PAR-24-230 from the NIH Guide for Grants and Contracts. The B-INSPIRE: Research on Behavioral INterventionS that Promote Careers In the Biomedical Research Enterprise Notice of Funding Opportunity (NOFO) encourages applications that propose research designed to conduct studies of behavioral interventions to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Applications that propose conducting secondary data analysis of rigorous interventions, leveraging existing intervention cohorts, using new or advanced methods of analysis of rigorous intervention datasets, or general novel combinations and integration of rigorous intervention datasets for analysis, are also encouraged. Funded projects are expected to produce research findings that will guide the implementation of behavioral interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.
Notice NOT-NS-24-107 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-25-195 from the NIH Guide for Grants and Contracts. This NOFO aims to encourage research using novel behavioral measures to foster a new generation of clinical signatures, leading toward precision assessment, prognosis, and treatment of mental disorders. The initial focus will be to (1) develop or optimize behavioral tasks that measure individual differences and demonstrate added utility for clinical prediction when combined with standard clinical diagnosis; (2) form a data infrastructure that can support computational approaches to build tools for clinical decision making.
Notice NOT-AG-24-021 from the NIH Guide for Grants and Contracts
Notice NOT-MD-24-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-069 from the NIH Guide for Grants and Contracts
Notice NOT-HL-24-007 from the NIH Guide for Grants and Contracts
Notice NOT-TR-24-029 from the NIH Guide for Grants and Contracts
Notice NOT-AG-24-022 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-24-035 from the NIH Guide for Grants and Contracts. This initiative will solicit applications that propose the development and early stage validation of next generation humanized small animal models and/or human cellular microphysiological systems that improve the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression.
Funding Opportunity PAR-24-223 from the NIH Guide for Grants and Contracts. The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.